Numinus Wellness Dirección

Dirección controles de criterios 3/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Payton Nyquvest

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	4yrs
Participación del CEO	2.6%
Permanencia media de la dirección	2.7yrs
Promedio de permanencia en la Junta Directiva	3.6yrs

Actualizaciones recientes de la dirección

Recent updates

Market Cool On Numinus Wellness Inc.'s (TSE:NUMI) Revenues Pushing Shares 30% Lower

Apr 17

Slammed 27% Numinus Wellness Inc. (TSE:NUMI) Screens Well Here But There Might Be A Catch

Feb 25

After Leaping 30% Numinus Wellness Inc. (TSE:NUMI) Shares Are Not Flying Under The Radar

Jan 05

Numinus Wellness Inc.'s (TSE:NUMI) Popularity With Investors Is Clear

Apr 17

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Payton Nyquvest en comparación con los beneficios de Numinus Wellness?
Fecha	Compensación total	Salario	Ingresos de la empresa
Feb 29 2024	n/a	n/a	-CA$27m
Nov 30 2023	n/a	n/a	-CA$28m
Aug 31 2023	n/a	n/a	-CA$30m
May 31 2023	n/a	n/a	-CA$46m
Feb 28 2023	n/a	n/a	-CA$45m
Nov 30 2022	n/a	n/a	-CA$46m
Aug 31 2022	CA$277k	CA$277k	-CA$45m
May 31 2022	n/a	n/a	-CA$28m
Feb 28 2022	n/a	n/a	-CA$26m
Nov 30 2021	n/a	n/a	-CA$22m
Aug 31 2021	CA$568k	CA$274k	-CA$19m
May 31 2021	n/a	n/a	-CA$14m
Feb 28 2021	n/a	n/a	-CA$13m
Nov 30 2020	n/a	n/a	-CA$11m
Aug 31 2020	CA$208k	CA$205k	-CA$10m

Compensación vs. Mercado: Datos insuficientes para determinar si la compensación total de Payton es razonable en comparación con empresas de tamaño similar en el mercado Canadian.

Compensación vs. Ingresos: La compensación de Payton ha sido consistente con los resultados de la empresa en el último año.

CEO

Payton Nyquvest

4yrs

Permanencia

CA$277,083

Compensación

Mr. Payton Nyquvest is a Founder of Numinus Wellness Inc. and also serves as its Chief Executive Officer since May 15, 2020 and serves as its Director since May 15, 2020 and serves as its Chairman since 20...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Payton Nyquvest	Founder	4yrs	CA$277.08k	2.63% CA$ 673.3k
Michael Tan	President	4yrs	CA$621.25k	0.76% CA$ 194.6k
Paul Thielking	Chief Science & Medical Officer	1.9yrs	CA$583.84k	0.0093% CA$ 2.4k
Reid Robison	Chief Clinical Officer	1.9yrs	CA$721.16k	0.34% CA$ 86.8k
Melony Valleau	Interim Chief Financial Officer	less than a year	sin datos	sin datos
Jamie Kokoska	Vice President of Investor Relations	no data	sin datos	sin datos
Paula Hewitt	Senior VP	no data	sin datos	sin datos
Ian Noble	Chief Communications Officer	3yrs	sin datos	sin datos
Danielle Hinan	Vice President Marketing	2.5yrs	sin datos	sin datos
Lea Bottoni	Vice President of People & Culture	2.9yrs	sin datos	sin datos
Judy Varga	Head of Laboratory Operations	3.5yrs	sin datos	sin datos
Jason Lapensee	Senior Vice President of Clinic Operations	1.3yrs	sin datos	0.0031% CA$ 800.1

2.7yrs

Permanencia media

50yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de NUMI se considera experimentado (2.6 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Payton Nyquvest	Founder	4yrs	CA$277.08k	2.63% CA$ 673.3k
Michael Tan	President	4yrs	CA$621.25k	0.76% CA$ 194.6k
Larry Timlick	Independent Director	5.3yrs	CA$162.38k	0.18% CA$ 46.5k
Allen Morishita	Independent Director	12.2yrs	CA$159.43k	0.31% CA$ 79.5k
Jamie Wheal	Member of General Advisory Counsel	3.6yrs	sin datos	sin datos
Ben Nemtin	Member of General Advisory Counsel	3.6yrs	sin datos	sin datos
Dennis McKenna	Member of General Advisory Counsel	3.6yrs	sin datos	sin datos
Pamela Hadfield	Member of General Advisory Counsel	3.6yrs	sin datos	sin datos
Nichol Bradford	Member of General Advisory Counsel	3.6yrs	sin datos	sin datos
Pam Kryskow	Member of the Clinical Advisory Council	3.5yrs	sin datos	sin datos
Gabor Mate	Member of the Clinical Advisory Council	3.5yrs	sin datos	sin datos
Zachary Walsh	Member of the Clinical Advisory Council	3.5yrs	sin datos	sin datos

3.6yrs

Permanencia media

Junta con experiencia: La junta directiva de NUMI se considera experimentada (3.5 años de antigüedad promedio).

Numinus Wellness Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Numinus Wellness Inc., Annual General Meeting, May 21, 2024

Numinus Wellness Inc., Annual General Meeting, Feb 26, 2024

Insufficient new directors

Numinus Wellness Inc. Appoints Nikhil Handa as Chief Financial Officer, Effective from June 15, 2023

Numinus Wellness Inc., Annual General Meeting, Feb 15, 2023

High number of new and inexperienced directors

Recent updates

Market Cool On Numinus Wellness Inc.'s (TSE:NUMI) Revenues Pushing Shares 30% Lower

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Numinus Wellness Inc. to Report Q2, 2024 Results on Apr 15, 2024

Numinus Wellness Inc. Submits Clinical Trial Application

Numinus Wellness Inc., Annual General Meeting, May 21, 2024

Slammed 27% Numinus Wellness Inc. (TSE:NUMI) Screens Well Here But There Might Be A Catch

Numinus Wellness Inc. has completed a Composite Units Offering in the amount of CAD 6 million.

First quarter 2024 earnings: EPS in line with expectations, revenues disappoint

After Leaping 30% Numinus Wellness Inc. (TSE:NUMI) Shares Are Not Flying Under The Radar

Numinus Wellness Inc., Annual General Meeting, Feb 26, 2024

Insufficient new directors

Full year 2023 earnings: EPS and revenues miss analyst expectations

Numinus Wellness Inc. to Report Q4, 2023 Results on Nov 29, 2023

Numinus Wellness Inc. Introduces Its Innovative and Comprehensive Psychedelic Program for Individuals Surging from Mental Distress Associated with Chronic and Serious Illness Through Cedar Clinical Research

Forecast to breakeven in 2026

Third quarter 2023 earnings: EPS misses analyst expectations

Numinus Wellness Inc. to Report Q3, 2023 Results on Jul 17, 2023

Numinus Wellness Inc. Appoints Nikhil Handa as Chief Financial Officer, Effective from June 15, 2023

Numinus Wellness Inc. Announces Cedar Clinical Research

Numinus Wellness Inc. Announces to Research COMP360 Psilocybin Therapy in Treatment-Resistant Depression as Part of Large Phase 3 Study

Numinus Wellness Inc Aligns Business Initiatives to Prepare for Future Approval of MDMA-Assisted Therapy

Numinus Wellness Inc.'s (TSE:NUMI) Popularity With Investors Is Clear

Second quarter 2023 earnings released: CA$0.028 loss per share (vs CA$0.038 loss in 2Q 2022)

Numinus Wellness Inc. Receives Clinical Trial Application Approval from Health Canada for Experiential Psychedelic-Assisted Therapy Training Using Psilocybe Cubensis Tea

First quarter 2023 earnings released: CA$0.024 loss per share (vs CA$0.026 loss in 1Q 2022)

Numinus Wellness Inc. to Report Q1, 2023 Results on Jan 16, 2023

Numinus Wellness Inc., Annual General Meeting, Feb 15, 2023

Numinus Wellness Inc. Submits Clinical Trial Application to Health Canada for Experiential Psilocybin Assisted Therapy Training Research

Full year 2022 earnings released: CA$0.21 loss per share (vs CA$0.11 loss in FY 2021)

Numinus Wellness Inc. Reports Impairment of Good Will for the Fourth Quarter Ended August 31, 2022

High number of new and inexperienced directors

Numinus Wellness Inc. Launches Psychedelic-Assisted Therapy for Chronic and Serious Medical Illness

Numinus Develops Mushroom Tea for Use in Psychedelic Research

Numinus Now Offers Ketamine-Assisted Therapy in Toronto

Numinus Wellness Inc. to Report Q4, 2022 Results on Nov 29, 2022

Third quarter 2022 earnings released: CA$0.033 loss per share (vs CA$0.025 loss in 3Q 2021)

Numinus Wellness Inc. to Report Q3, 2022 Results on Jul 14, 2022

Numinus Wellness Inc. Announces Launch of Pilots Mental Health Program for Corporate Clients in Utah

Numinus Wellness Inc. Announces That Its Subsidiary Numinus Bioscience Inc Applies for International Patent Filing of Psychedelics Production Process

Numinus Wellness Inc. (TSX:NUMI) completed the acquisition of Novamind Inc. (OTCPK:NVMD.F).

Numinus Wellness Inc. Receives Health Canada Special Access Program Applicant Approval to Provide Psychedelic-assisted Therapy Treatment

Numinus Announces the Music as Medicine Event Series

High number of new and inexperienced directors

Second quarter 2022 earnings released: CA$0.038 loss per share (vs CA$0.028 loss in 2Q 2021)

Numinus Wellness Inc. (TSX:NUMI) entered into a definitive agreement to acquire Novamind Inc. (OTCPK:NVMD.F) for CAD 21.6 million.

Numinus Wellness Inc. to Report Q2, 2022 Results on Apr 14, 2022

Numinus Wellness Inc. Completes First MDMA Administration in PTSD Trial Sponsored by MAPS

Numinus Wellness Inc. Appoints New Bioscience Advisors to Advance IP Development

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Psilocybin and MDMA Get the Green Light for Medical Use in Canada

Numinus Submits Clinical Trial Application for Phase 1 Trial on Proprietary Psilocybin Product

Numinus Wellness Inc.(TSXV:NUMI) dropped from S&P/TSX Venture Composite Index

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Numinus Wellness Inc. (TSXV:NUMI) completed the acquisition of Neurology Centre of Toronto.

Third quarter 2021 earnings released: CA$0.025 loss per share (vs CA$0.035 loss in 3Q 2020)

Numinus Announces Health Canada Approval of MAPS-Sponsored Open Label Study for MDMA-Assisted Therapy for Post-Traumatic Stress Disorder

Optimi Health and Numinus Wellness Inc. Completes Pre-Clinical Trial Application Meeting

Numinus Wellness and Optimi Health Submit All-Natural Psilocybin Extract to Health Canada for Pre-Clinical Trial Application

Numinus Wellness Inc. Congratulates Multidisciplinary Association for Psychedelic Studies on Phase 3 Clinical Trial Demonstrating Significant Benefits of MDMA-Assisted Therapy for Severe PTSD

Second quarter 2021 earnings released: CA$0.028 loss per share (vs CA$0.016 loss in 2Q 2020)

Independent Director exercised options to buy CA$158k worth of stock.

Numinus Wellness Inc. has completed a Composite Units Offering in the amount of CAD 35 million.

Numinus Wellness Inc. Receives New Amendments Under Canada's Controlled Drugs and Substances Act Enhance the Company's Ability to Lead Psychedelics Research and Support the Global Psychedelics Sector

Optimi Health and Numinus Wellness to Conduct Psychedelic Lab Research and Development

Numinus and Syreon Provide Psilocybin Compassionate Access Trial Update

Numinus Wellness Inc Announces Milestones in Compassionate Access Trial for Mdma-Assisted Therapy in Collaboration with Maps Public Benefit Corporation

Independent Director recently sold CA$54k worth of stock

Independent Director recently sold CA$54k worth of stock

Numinus Wellness Inc. (TSXV:NUMI) completed the acquisition of Mindspace Psychology Services Inc.